Abstract:Objective To investigate the clinical effect of Ligustrazine and Glucagon-like Peptide 1 (GLP-1) Receptor Agonist in the treatment of chronic complications of type 2 diabetes (T2DM). Methods From January to June 2019, 90 cases of chronic complications of T2DM treated in our hospital were selected and were divided into three groups:Ligustrazine group (n=30), the agonist group (n=30) and the combined group (n=30) according to the random number table method. All three groups were treated with oral treatment, diet guidance and health education to complete the disease treatment. The Ligustrazin group was given Ligustrazin intravenous drip; the agonist group was treated with GLP-1 Receptor Agonist; the combined group was treated with Ligustrazin and GLP-1 Receptor Agonist. After treatment, the clinical efficacy, blood glucose, erythrocyte aldose reductase (AR) activity and glycosylated hemoglobin (HbA1c) were compared among the three groups. Results The total effective rate of the combined group was 100.0%, which was higher than those of the Ligustrazin group (83.3%) and the agonist group (86.7%) (P<0.05), but there was no significant difference between the Ligustrazin group and the agonist group (P>0.05). The activity of fasting blood sugar (FPG), 2 hours postprandial blood glucose (2 hPG), AR and HbA1c in the combined group were lower than those in the Ligustrazine group and the agonist group, and the differences were statistically significant (P<0.05), but there was no significant difference between the Ligustrazin group and the agonist group (P>0.05). Conclusion On the basis of routine active intervention, the combination of Ligustrazine and GLP-1 Receptor agonist in patients with chronic complications of T2DM has more positive and obvious effect, which is of great value in terms of short-term and long-term curative effects.
陈再明. 川芎嗪与胰高血糖素样肽-1受体激动剂治疗2型糖尿病慢性并发症的临床效果[J]. 中国当代医药, 2020, 27(6): 40-42.
CHEN Zai-ming. Clinical effect of Ligustrazine and Glucagon-like Peptide 1 Receptor Agonist in the treatment of chronic complications of type 2 diabetes. 中国当代医药, 2020, 27(6): 40-42.